Schrödinger, Inc. develops a physics-based computational platform that enables the discovery of novel molecules for drug development and materials applications. The company operates in two primary seg... Schrödinger, Inc. develops a physics-based computational platform that enables the discovery of novel molecules for drug development and materials applications. The company operates in two primary segments: Software and Drug Discovery. The Software segment provides advanced computational tools to biopharmaceutical and biotechnology companies, as well as materials science firms, transforming molecular discovery processes in life sciences and related industries. The Drug Discovery segment builds a portfolio of preclinical and clinical programs, advancing proprietary candidates like the MALT1 inhibitor SGR-1505 and pursuing collaborations with partners such as Novartis, Lilly, Ajax Therapeutics, and Copernic Catalysts to target specific therapeutic areas including oncology and rare diseases. Founded in 1990 and headquartered in New York, Schrödinger, Inc. plays a pivotal role in accelerating innovation at the intersection of computational chemistry, AI-driven simulations, and drug design, supporting research from target identification through clinical validation.Show lessShow more

Disclosures ESG Data Financial Data

GHG Emissions Climate Targets EU Taxonomy Energy Waste Management

Data not available

Schrodinger is not subject to EU Taxonomy reporting

Based on current regulatory requirements, Schrodinger is not required to report EU Taxonomy data under the CSRD framework. As a result, we have not conducted a detailed EU Taxonomy data review for this company.

If you believe this assessment should be revisited, you may submit a data coverage request and our team will review the company's regulatory applicability.

Would you like us to review Schrodinger's data?

Start your 30-day free trial to request a data review for Schrodinger.

Start Free Trial

Legal Center Contact Us